A Phase II Trial of Perioperative CV301 Vaccination in Combination with Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer
To determine if pre-surgery vaccination with CV301 in combination with Nivolumab, chemotherapy, and surgery will improve the overall survivial compared to pre-surgery Nivolumab, chemotherapy, and surgery in patients with liver-limited (hepatic-limited) metastatic colorectal cancer.
Hepatic-limited colorectal cancer
-Age ≥ 18 years at the time of consent.
-ECOG Performance Status of ≤ 2 and/or sufficient to undergo both perioperative systemic chemotherapy and hepatic surgery as determined by surgical and medical oncology evaluations.
-Histologically confirmed hepatic-limited metastatic colorectal cancer
18 - 150
Healthy Volunteers Needed
Duration of Participation
Knight Clinical Trials Information Line
Hoosier Cancer Research Network, Inc.